



Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Treatment naïve mantle cell lymphoma (MCL)
 - a. Used in combination with bendamustine and rituximab
 - b. Patient is ineligible for autologous hematopoietic stem cell transplantation (HSCT)
2. Previously treated mantle cell lymphoma (MCL)
 - a. Patient has received at least one prior therapy
 - b. Used as a single agent
3. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
 - a. **AND ONE** of the following:
 - i. Used as a single agent
 - ii. Used in combination with Gazyva (obinutuzumab) as first-line therapy for CLL or SLL

AND ALL of the following for **ALL** indications:

- a. Prescriber agrees to do a baseline CBC and monitor monthly during therapy
- b. Prescriber agrees to monitor for malignancies
- c. Prescriber agrees to monitor for bleeding

Prior - Approval Limits

Quantity 200 mg per day

Duration 12 months



Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Mantle cell lymphoma (MCL)
2. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

AND ALL of the following for **ALL** indications:

- a. Prescriber agrees to monitor CBC monthly during therapy
- b. Prescriber agrees to monitor for malignancies
- c. Prescriber agrees to monitor for bleeding
- d. **NO** disease progression or unacceptable toxicity

Prior - Approval *Renewal* Limits

Same as above